In the context of Parkinson’s disease treatment, inhibiting USP30 increases translocase of outer mitochondrial membrane 20 (TOM20) ubiquitination and promotes mitophagy, offering a potential therapeutic strategy for Parkinson’s disease caused by PTEN-induced kinase 1 (PINK1) or Parkin mutations (Fang et al., 2023). This evidence concerns the gene TOMM20 and Parkinson disease.